Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > And That's Not All

<< Previous

Bullboard Posts

Next >>

Post by Probosciseson Mar 03, 2023 7:29pm

741 Views

Post# 35318793

And That's Not All

During the year end conference call a few other items were mentioned by Heineman and de Guttadauro besides stuff about breast and pancreatic cancer.

Tom Heineman: "Lastly, before handing off the call to Andrew, I would like to remind all listening that in addition to its pancreatic cancer cohort, GOBLET also includes cohorts evaluating pela atezolizumab combinations in metastatic colorectal and advanced anal cancer. We expect to have additional updates from these cohorts over the course of the year and have been pleased with the overall enrollment to date."

Andrew de Guttadauro: "One final note, we continue to advance our preclinical CAR-T program in ongoing discussions with multiple potential biopharma and research partners and maintain constructive conversations on a potential clinical trial."

In these conference calls time is limited and company participants tend to mention only those things they consider important. In this case Heineman mentioned metastatic colorectal and anal cancer, and de Guttadauro mentioned CAR-T. As I discussed in earlier posts I believe we are getting hints that outcomes in the trials with Pela in colorectal and anal cancer, and the animal trial with Pela in combination withb CAR-T are looking good.

Notice what was said in the year end Financial Results and Operational Highlights:

2023 Anticipated Milestones and Catalysts

Overall response rate, progression-free survival, and evolving overall survival data from phase 2 BRACELET-1 metastatic breast cancer study: Q2 2023
Preclinical data from the combination of pelareorep and CAR T therapy: Q2 2023
Updated advanced/metastatic PDAC data from the GOBLET study: H2 2023
Updates on the metastatic colorectal and advanced anal cohorts from the GOBLET study: H2 2023
Guidance for the registration paths for HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC: H2 2023